<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308619</url>
  </required_header>
  <id_info>
    <org_study_id>US10150</org_study_id>
    <nct_id>NCT01308619</nct_id>
  </id_info>
  <brief_title>Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg
      immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo
      in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with
      rosacea-related inflammatory markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Inflammatory Lesion Counts</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Mean change in inflammatory lesion counts from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 [LL-37] peptide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA) Scores at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician's Erythema Assessment (CEA) Scores</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Oracea®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning</description>
    <arm_group_label>Oracea®</arm_group_label>
    <other_name>Oracea®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, oral, one capsule daily in the morning</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female aged 18 to 70 years inclusive

          -  Subject with papulopustular rosacea (5 to 40 papules or pustules)

        Exclusion Criteria:

          -  Subject has any other active dermatological condition on face that may interfere with
             the conduct of the study

          -  Subject uses proton pump inhibitors for treatment of gastroesophageal reflux within 30
             days prior to baseline visit or during the study

          -  Subject uses spironolactone within 30 days prior to baseline visit or during the study

          -  Subject requires chronic treatment (&gt;14 days) with sulfa drugs, erythromycin,
             cephalosporins and quinolones within 30 days prior to baseline visit or during the
             study

          -  Subject has used tetracycline antibiotics within 30 days prior to baseline visit or
             during the study

          -  Subject has used penicillin antibiotics within 30 days prior to baseline visit or
             during the study

          -  Subject uses topical or oral dapsone

          -  Subject has had a change in hormonal therapy within 3 months of initiation of therapy
             or during the study

          -  Subject has used systemic immunosuppressants (e.g. corticosteroids, cyclosporine,
             imuran, biologics, mycophenolate mofetil) within 30 days prior to baseline visit. For
             subjects who have received treatment with biologics, treatment must have been
             discontinued within 90 days prior to baseline

          -  Subject has used any systemic therapy directed at improving rosacea, including
             antibiotics, within 30 days prior to baseline visit

          -  Subject has used systemic retinoids within 6 months of the baseline visit

          -  Subject takes niacin at a dosage of 500 mg or more per day

          -  Subject has used any topical rosacea therapy including topical antibiotics, topical
             retinoids, topical sodium sulfacetamide preparations, topical benzoyl peroxides,
             topical vasoconstricting agents (e.g., oxymetazoline) topical calcineurin inhibitors
             (e.g. tacrolimus, pimecrolimus) within 30 days prior to baseline visit

          -  Subject has been treated with another investigational drug or device within 30 days of
             baseline visit. For subjects who received experimental biologic treatment, treatment
             must have been discontinued within five half lives of the baseline visit.

          -  Subject has a known allergy to any of the components of the study products, and/or a
             known hypersensitivity to tetracyclines

          -  Subject is using a clinically significant concomitant drug (e.g., use of long term
             non-steroidal anti-inflammatory agents unless used only on a PRN basis less than 7
             days per month)

          -  Subject has used vasodilators or an adrenergic blocking agent within 6 weeks of
             baseline visit (except subjects on stable dose for greater than 3 months)

          -  Subject has had laser or light therapy on the face within 3 months of the baseline
             visit

          -  Subject with active ocular rosacea and/or blepharitis/meibomianitis requiring systemic
             treatment by an ophthalmologist

          -  Subject with rhinophymatous rosacea

          -  Subject with a history of noncompliance with a treatment regimen

          -  Subject is at risk in terms of precautions, warnings, and contraindications (see
             package insert)

          -  Subject has previously failed to have improvement of rosacea with appropriate use of
             systemic tetracycline family of antibiotics

          -  Subjects with a recent history of alcohol and/or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Dermatology</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Corp</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <results_first_submitted>November 11, 2013</results_first_submitted>
  <results_first_submitted_qc>July 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2014</results_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled 9 May 2011, last subject last visit 2 July 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oracea®</title>
          <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Capsules</title>
          <description>Placebo capsules for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oracea®</title>
          <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="11.4"/>
                    <measurement group_id="B2" value="48.7" spread="10.8"/>
                    <measurement group_id="B3" value="49.1" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Inflammatory Lesion Counts</title>
        <description>Mean change in inflammatory lesion counts from baseline to week 12</description>
        <time_frame>baseline to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oracea®</title>
            <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Lesion Counts</title>
          <description>Mean change in inflammatory lesion counts from baseline to week 12</description>
          <units>inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="7.9"/>
                    <measurement group_id="O2" value="-3.2" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12</title>
        <description>Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 [LL-37] peptide.</description>
        <time_frame>baseline to week 12</time_frame>
        <population>Treatment success was defined as all subjects from either treatment group with a score of clear or near clear on the Investigator’s Global Assessment (IGA) scale. Treatment failure was defined as all subjects from either treatment group with a score of mild, moderate, or severe on the IGA scale.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Success</title>
          </group>
          <group group_id="O2">
            <title>Treatment Failure</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12</title>
          <description>Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 [LL-37] peptide.</description>
          <population>Treatment success was defined as all subjects from either treatment group with a score of clear or near clear on the Investigator’s Global Assessment (IGA) scale. Treatment failure was defined as all subjects from either treatment group with a score of mild, moderate, or severe on the IGA scale.</population>
          <units>micr grams protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cathelicidin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0931" spread="0.5491"/>
                    <measurement group_id="O2" value="-0.0379" spread="0.1545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0034" spread="0.0110"/>
                    <measurement group_id="O2" value="-0.0049" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0017" spread="0.0100"/>
                    <measurement group_id="O2" value="-0.0021" spread="0.0233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22351.6" spread="102888.2"/>
                    <measurement group_id="O2" value="-22540.9" spread="66146.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator's Global Assessment (IGA) Scores at Week 12</title>
        <description>Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oracea®</title>
            <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Assessment (IGA) Scores at Week 12</title>
          <description>Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Near Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinician's Erythema Assessment (CEA) Scores</title>
        <description>Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.</description>
        <time_frame>baseline to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oracea®</title>
            <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinician's Erythema Assessment (CEA) Scores</title>
          <description>Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.9"/>
                    <measurement group_id="O2" value="-0.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oracea®</title>
          <description>Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>unlikely related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous abortion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Warren Winkelman</name_or_title>
      <organization>Galderma Laboratories</organization>
      <phone>817-961-5494</phone>
      <email>warren.winkelman@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

